Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis

Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis

Abstract Background The KEYNOTE-048 trial showed that pembrolizumab-based first-line treatment for R/M HNSCC led to improved OS in the PD-L1 CPS ≥ 1 population when compared to the EXTREME regimen. However, the R/M HNSCC real-world population is generally frailer, often presenting with multiple como...

Full description

Bibliographic Details
Main Authors: Alessio Cirillo, Daniele Marinelli, Umberto Romeo, Daniela Messineo, Francesca De Felice, Marco De Vincentiis, Valentino Valentini, Silvia Mezi, Filippo Valentini, Luca Vivona, Antonella Chiavassa, Bruna Cerbelli, Daniele Santini, Paolo Bossi, Antonella Polimeni, Paolo Marchetti, Andrea Botticelli
Format: Article
Language:English
Published: BMC 2024-04-01
Series:BMC Cancer
Subjects:
HNSCC
Immunotherapy
PD-L1
Biomarkers
Pembrolizumab
Online Access:https://doi.org/10.1186/s12885-024-12155-3

Internet

https://doi.org/10.1186/s12885-024-12155-3

Similar Items